- Nova Mentis (NOVA) has signed a research agreement with the University of Central Florida (UCF) Research Foundation to develop a saliva serotonin assay
- Dr. Kiminobu Sugaya, a Professor and Head of Neuroscience in the Burnett School of Biomedical Science at UCF, will measure serotonin levels in the saliva samples collected as part of NOVA autism spectrum disorder (ASD) observational study
- Nova Mentis is a biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders
- Nova Mentis Life Science Corp. (NOVA) was up 12.50 per cent, trading at C$0.09 per share at 12:38 pm ET
Nova Mentis (NOVA) has signed a research agreement with the University of Central Florida (UCF) Research Foundation to develop a saliva serotonin assay.
Dr. Kiminobu Sugaya, a Professor and Head of Neuroscience in the Burnett School of Biomedical Science at UCF, will measure serotonin levels in the saliva samples collected as part of NOVA autism spectrum disorder (ASD) observational study.
Dr. Marvin S. Hausman MD, the Chairman of NOVA’s Scientific Advisory Board commented on the announcement.
“Serotonin is a key neurotransmitter that has been implicated in the development of autism spectrum disorder. The ability to measure its levels in a patient’s saliva will potentially assist NOVA in predicting disease development and in establishing specific treatable subsets of diseases that makeup the ‘spectrum’ called autism.”
NOVA has recently launched an IRB approved ASD observational study in North America where it collects specimens of a patient’s saliva and buccal cheek cells. The cheek cells and serotonin saliva levels will allow study of the neuroinflammatory mRNA genetic profile of ASD patients.
The research objective is to develop a genetic neuroinflammatory and serotonin data bank that will help establish a “Diagnostic Index”. These set of tools will help differentiate subtypes of ASD and the major genetic subset of ASD, fragile X syndrome (FXS), and help develop more accurate methods of diagnosis and treatment.
Customized machine learning algorithms will analyze the collected data. It will be used to guide design of upcoming clinical trials that will test the efficacy of psilocybin-based therapeutics in ASD and FXS.
Nova Mentis is a biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
Nova Mentis Life Science Corp. (NOVA) was up 12.50 per cent, trading at C$0.09 per share at 12:38 pm ET.
